Digital health and digital biomarkers – enabling value chains on health data

Meister, Sven; Deiters, Wolfgang; Becker, Stefan

doi:10.1515/cdbme-2016-0128

Cited by 44 publications

(27 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Aside from the immediate financial benefits generated for electronic health records platform companies, such as Epic or Cerner, 3 HITECH also created massive pools, lakes, or oceans, of patient data that hospitals, clinics, public health, and insurers can mine for myriad purposes. Perhaps an apocryphal notion that data is a natural resource to be tapped, which originated in the consumer data industry, many in medicine and healthcare understand patient data as the “new oil”; it is understood as a resource, a well of pluripotent information, that clinicians, researchers, administrators, and commercial actors need access to in order to tap the value locked inside the raw data (Hovet, 2018; Meister et al, 2016). This new resource was created by the healthcare industry, through the combination of shaping legislation and marketing digital platforms, and it is the EHR vendors and the data industry that stand to benefit the most.…”

Section: The Hitech Act and Access To Health Recordsmentioning

confidence: 99%

Patient disempowerment through the commercial access to digital health records

Ebeling

2019

Health (London)

View full text Add to dashboard Cite

In this article, I consider how patients are disempowered through the commercial access to their health data in the United States. I examine two healthcare information technology bills that ostensibly give patients access and control over their health records. However, I contend that, since these regulations were drafted, in part or in whole, by corporate interests represented by healthcare lobbyists, policymakers use the rhetorical device of patient empowerment to allow for the commercial access to patient data, which ultimately disempowers patients. This is because in both bills the asymmetrical relationship to patient data remains the same: patients do not have ownership or control over the data that they produce. Rather, policymakers legislatively cede control over patient data to commercial interests.

show abstract

Section: The Hitech Act and Access To Health Recordsmentioning

confidence: 99%

Patient disempowerment through the commercial access to digital health records

Ebeling

2019

Health (London)

View full text Add to dashboard Cite

show abstract

“…[50] In the following seven decades we have witnessed tremendous progress in disease management and he would surely be enlightened by the repertoire of options we have available at our disposal to achieve patient homeostasis. [51] The strategy of playing late-stage disease ‘whack-a-mole’ using combination chemotherapeutics is being supplanted by methods which offer digital and molecular level precision, and promise to transform medicine in ways previously unimaginable to us. [52] Warning signs on the need for the pharmaceutical industry to entertain new business models are legion.…”

Section: Discussionmentioning

confidence: 99%

Harnessing the Digital Exhaust: Incorporating Wellness into the Pharma Model

Wright

Jones

2018

Digit Biomark

View full text Add to dashboard Cite

The increasing availability of devices capable of tracking biomarkers presents major opportunities in contemporary healthcare. Herein we advocate a new role for the pharmaceutical industry to capitalize on these opportunities and, in doing so, incorporate wellness and patient engagement programs into their standard business models. Medical-grade decision-making using diagnostic, prognostic, and monitoring biomarkers will require coordinated approaches between the pharmaceutical and technology industries and the careful design of longitudinal clinical studies to validate their efficacy. These studies will also require data capture, archiving, curating, and sharing on a previously unprecedented scale, and raise additional concerns with regard to data security and ownership. Concurrently, systems-based approaches to the capture and interpretation of a new class of digital biomarkers are emerging, and they hold promise for heightened levels of patient engagement and remote sensing. Collectively, if these new opportunities are approached within the context of the patient-provider ecosystem, major repositioning of the pharmaceutical industry may be possible in the near future.

show abstract

“…We limited the search from January 2000 to October 2019 as the emergence of mobile health (mHealth) and digital health started after the year 2000. 25 We also searched grey literature sources, such as ProQuest Dissertations and Theses, Research Gate, Google Scholar, Opengrey, and Google. Appendix B shows the keywords for Google, Google Scholar, and ResearchGate.…”

Section: Search Strategymentioning

confidence: 99%

Facilitators and barriers of using digital technology for the management of diabetic foot ulcers: A qualitative systematic review

Foong

Kyaw

Upton

et al. 2020

International Wound Journal

View full text Add to dashboard Cite

The use of digital technology has been shown to be effective in managing chronic conditions. Telemedicine and mobile application are two common applications of digital technology in managing diabetic foot ulcers (DFU). The facilitators and barriers of using it for DFU management are yet to be explored. This is a qualitative systematic review. Five bibliography databases and grey literature sources were searched (2000‐2019). Two reviewers independently screened the citations, extracted the data, assessed the quality of the included studies, and performed thematic synthesis. Three studies on patients and five studies on healthcare practitioners (HCPs) were included. Two studies focused on the use of mobile applications and six on telemedicine. In studies on patients, four analytical themes were generated: the relationships with HCPs; the attitude towards the usage of digital technology; the role of wound image taking; and impact of digital technology on DFU care, encompassing 15 facilitators (eg, enabling community support, improving wound care knowledge) and 12 barriers (eg, lack of technological savviness, difficulty reading on smartphones). Three analytical themes were generated from studies on HCPs: the impact of digital technology on HCPs; the role of digital technology in DFU care; and organisation of DFU care delivery, encompassing 17 facilitators (eg, adequate wound care training, digital technology enables holistic care) and 16 barriers (eg, lack of multidisciplinary approach in caring for DFU, lack of direct contact in care provision). Patients and HCPs reported various barriers and facilitators relating to different aspects of using digital technology in DFU management. Our findings can help inform future research as well as the adoption of digital technology in DFU management.

show abstract

Digital health and digital biomarkers – enabling value chains on health data

Cited by 44 publications

References 14 publications

Patient disempowerment through the commercial access to digital health records

Patient disempowerment through the commercial access to digital health records

Harnessing the Digital Exhaust: Incorporating Wellness into the Pharma Model

Facilitators and barriers of using digital technology for the management of diabetic foot ulcers: A qualitative systematic review

Contact Info

Product

Resources

About